Elsayad Khaled, Moustakis Christos, Simonsen Manuela, Bäcker Dagmar, Haverkamp Uwe, Eich Hans Theodor
Department of Radiation Oncology, University Hospital of Münster, Münster, Germany.
Phys Imaging Radiat Oncol. 2018 May 19;6:61-65. doi: 10.1016/j.phro.2018.05.002. eCollection 2018 Apr.
Thermoluminescent dosimetry (TLD) is an important element of total skin electron beam therapy (TSEBT). In this study, we compare radiation dose distributions to provide data for dose variation across anatomic sites.
Retrospectively collected data on 85 patients with cutaneous lymphoma or leukemia underwent TSEBT were reviewed. Patients were irradiated on two linear accelerators, in one of two positions (standing, n = 77; reclined, n = 8) and 1830 in vivo TLD measurements were obtained for various locations on 76 patients.
The TLD results showed that the two TSEBT techniques were dosimetrically heterogeneous. At several sites, the dose administered correlated with height, weight, and gender. After the first TLD measurement, fourteen patients (18%) required MU modification, with a mean 10% reduction (range, -25 to +35). Individual TLD results allowed us to customize the boost treatment for each patient. For patients who were evaluated in the standing position, the most common underdosed sites were the axilla, perineum/perianal folds, and soles (each receiving 69%, 20%, and 34% of the prescribed dose, respectively). For patients evaluated in a reclining position, surface dose distribution was more heterogeneous. The sites underdosed most commonly were the axilla and perineum/perianal folds (receiving less than one third of prescribed dose). Significant variables were detected with model building.
TLD measurements were integral to quality assurance for TSEBT. Dose distribution at several anatomical sites correlated significantly with gender, height, and weight of the treated individual and might be predicted.
热释光剂量测定法(TLD)是全身皮肤电子束治疗(TSEBT)的重要组成部分。在本研究中,我们比较辐射剂量分布,以提供不同解剖部位剂量变化的数据。
回顾性分析85例接受TSEBT的皮肤淋巴瘤或白血病患者的数据。患者在两台直线加速器上接受照射,处于两个位置之一(站立,n = 77;仰卧,n = 8),并对76例患者的不同部位进行了1830次体内TLD测量。
TLD结果显示,两种TSEBT技术在剂量学上存在异质性。在几个部位,给予的剂量与身高、体重和性别相关。首次TLD测量后,14例患者(18%)需要调整MU,平均减少10%(范围为-25%至+35%)。个体TLD结果使我们能够为每位患者定制强化治疗。对于站立位评估的患者,最常见的剂量不足部位是腋窝、会阴/肛周皱襞和脚底(分别接受规定剂量的69%、20%和34%)。对于仰卧位评估的患者,表面剂量分布更不均匀。最常见的剂量不足部位是腋窝和会阴/肛周皱襞(接受的剂量不到规定剂量的三分之一)。通过模型构建检测到显著变量。
TLD测量是TSEBT质量保证的组成部分。几个解剖部位的剂量分布与治疗个体的性别、身高和体重显著相关,并且可能可以预测。